DNAPrint Current Ratio from 2010 to 2026
DNAPrint Genomics' Current Ratio is decreasing over the last several years with very volatile swings. Current Ratio is predicted to flatten to 0.34. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
Current Ratio | First Reported 2010-12-31 | Previous Quarter 0.57 | Current Value 0.34 | Quarterly Volatility 0.09980985 |
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
DNAPrint | Current Ratio | Build AI portfolio with DNAPrint Stock |
The Current Ratio trend for DNAPrint Genomics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether DNAPrint Genomics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest DNAPrint Genomics' Current Ratio Growth Pattern
Below is the plot of the Current Ratio of DNAPrint Genomics over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. DNAPrint Genomics' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DNAPrint Genomics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.17 X | 10 Years Trend |
|
Current Ratio |
| Timeline |
DNAPrint Current Ratio Regression Statistics
| Arithmetic Mean | 0.60 | |
| Geometric Mean | 0.59 | |
| Coefficient Of Variation | 16.68 | |
| Mean Deviation | 0.06 | |
| Median | 0.64 | |
| Standard Deviation | 0.1 | |
| Sample Variance | 0.01 | |
| Range | 0.3043 | |
| R-Value | (0.05) | |
| Mean Square Error | 0.01 | |
| R-Squared | 0 | |
| Significance | 0.84 | |
| Slope | (0) | |
| Total Sum of Squares | 0.16 |
DNAPrint Current Ratio History
About DNAPrint Genomics Financial Statements
DNAPrint Genomics stakeholders use historical fundamental indicators, such as DNAPrint Genomics' Current Ratio, to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DNAPrint Genomics' assets and liabilities are reflected in the revenues and expenses on DNAPrint Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DNAPrint Genomics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.57 | 0.34 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.